{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T16:08:56Z","timestamp":1790266136954,"version":"4.1.0"},"reference-count":28,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,4,18]],"date-time":"2026-04-18T00:00:00Z","timestamp":1776470400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004543","name":"China Scholarship Council","doi-asserted-by":"publisher","award":["202208500008"],"award-info":[{"award-number":["202208500008"]}],"id":[{"id":"10.13039\/501100004543","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","esmorwd.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["ESMO Real World Data and Digital Oncology"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.esmorw.2026.100722","type":"journal-article","created":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T18:16:03Z","timestamp":1787595363000},"page":"100722","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Treatment and survival of de novo HER2-positive metastatic breast cancer across regional cancer networks in the Netherlands: a cohort study"],"prefix":"10.1016","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0009-0004-5719-0738","authenticated-orcid":false,"given":"N.","family":"Ding","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.M.E.","family":"Geurts","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7629-0820","authenticated-orcid":false,"given":"K.E.P.E.","family":"Hermans","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4550-3715","authenticated-orcid":false,"given":"I.J.H.","family":"Vriens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-6279-9917","authenticated-orcid":false,"given":"R.","family":"Visserman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.F.S.","family":"Kooreman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.A.J.B.","family":"Peters","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2999-2336","authenticated-orcid":false,"given":"E.M.","family":"Heuts","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Verloop","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8041-2720","authenticated-orcid":false,"given":"A.C.","family":"Voogd","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V.C.G.","family":"Tjan-Heijnen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.esmorw.2026.100722_bib1","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1053\/j.seminoncol.2020.07.008","article-title":"Systemic therapy for metastatic HER2-positive breast cancer","volume":"47","author":"Bredin","year":"2020","journal-title":"Semin Oncol"},{"issue":"4","key":"10.1016\/j.esmorw.2026.100722_bib2","first-page":"2884","article-title":"De novo metastatic breast cancer: subgroup analysis of molecular subtypes and prognosis","volume":"19","author":"Zhang","year":"2020","journal-title":"Oncol Lett"},{"issue":"8","key":"10.1016\/j.esmorw.2026.100722_bib3","doi-asserted-by":"crossref","first-page":"1194","DOI":"10.1093\/annonc\/mdz173","article-title":"Early breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up\u2020","volume":"30","author":"Cardoso","year":"2019","journal-title":"Ann Oncol"},{"issue":"16","key":"10.1016\/j.esmorw.2026.100722_bib4","doi-asserted-by":"crossref","first-page":"1673","DOI":"10.1056\/NEJMoa052122","article-title":"Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer","volume":"353","author":"Romond","year":"2005","journal-title":"N Engl J Med"},{"issue":"8","key":"10.1016\/j.esmorw.2026.100722_bib5","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1056\/NEJMoa1413513","article-title":"Pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancer","volume":"372","author":"Swain","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.esmorw.2026.100722_bib6","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.ejca.2018.03.015","article-title":"Time trends of overall survival among metastatic breast cancer patients in the real-life ESME cohort","volume":"96","author":"Gobbini","year":"2018","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.esmorw.2026.100722_bib7","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejca.2025.115475","article-title":"Overall survival of patients with de novo HER2-positive metastatic breast cancer in the Netherlands from 2008 to 2017: a population-based cohort study of systemically treated patients","volume":"222","author":"Ding","year":"2025","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.esmorw.2026.100722_bib8","doi-asserted-by":"crossref","DOI":"10.1016\/j.breast.2025.104417","article-title":"Disparities in access to anti-HER2 therapies in neoadjuvant chemotherapy: a prognostic analysis based on real-world data comparing Brazil\u2019s public and private healthcare systems","volume":"80","author":"Antonini","year":"2025","journal-title":"Breast"},{"key":"10.1016\/j.esmorw.2026.100722_bib9","article-title":"Real-world treatment patterns and outcomes among patients with HER2-positive unresectable or metastatic breast cancer in China","volume":"15","author":"Huang","year":"2025","journal-title":"Front Oncol"},{"issue":"3","key":"10.1016\/j.esmorw.2026.100722_bib10","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2021.100114","article-title":"Evolution of overall survival and receipt of new therapies by subtype among 20 446 metastatic breast cancer patients in the 2008-2017 ESME cohort","volume":"6","author":"Grinda","year":"2021","journal-title":"ESMO Open"},{"issue":"suppl 4","key":"10.1016\/j.esmorw.2026.100722_bib11","article-title":"201P Implementation of first-line pertuzumab and the impact on overall survival in patients with de novo HER2+ metastatic breast cancer in the Netherlands in 2008-2017: a population-based cohort","volume":"9","author":"Ding","year":"2024","journal-title":"ESMO Open"},{"issue":"10","key":"10.1016\/j.esmorw.2026.100722_bib12","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1038\/s41416-023-02439-z","article-title":"Evidence into practice: a national cohort study of NICE-recommended oncological drug therapy utilisation among women with invasive breast cancer in England","volume":"129","author":"Gannon","year":"2023","journal-title":"Br J Cancer"},{"issue":"12","key":"10.1016\/j.esmorw.2026.100722_bib14","doi-asserted-by":"crossref","first-page":"2914","DOI":"10.1158\/1055-9965.EPI-05-0317","article-title":"Regional differences in breast cancer survival despite common guidelines","volume":"14","author":"Eaker","year":"2005","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"issue":"31","key":"10.1016\/j.esmorw.2026.100722_bib15","doi-asserted-by":"crossref","first-page":"3997","DOI":"10.1200\/JCO.2013.50.9984","article-title":"Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology\/College of American Pathologists clinical practice guideline update","volume":"31","author":"Wolff","year":"2013","journal-title":"J Clin Oncol"},{"issue":"suppl 6","key":"10.1016\/j.esmorw.2026.100722_bib16","doi-asserted-by":"crossref","first-page":"vi7","DOI":"10.1093\/annonc\/mdt284","article-title":"Primary breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"24","author":"Senkus","year":"2013","journal-title":"Ann Oncol"},{"key":"10.1016\/j.esmorw.2026.100722_bib30","series-title":"TNM Classification of Malignant Tumours","year":"2009"},{"key":"10.1016\/j.esmorw.2026.100722_bib31","series-title":"TNM Classification of Malignant Tumours","author":"Brierley","year":"2017"},{"issue":"3","key":"10.1016\/j.esmorw.2026.100722_bib17","first-page":"1","article-title":"mice: multivariate imputation by chained equations in R","volume":"45","author":"van Buuren","year":"2011","journal-title":"J Stat Softw"},{"issue":"12","key":"10.1016\/j.esmorw.2026.100722_bib18","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1016\/j.annonc.2021.09.019","article-title":"ESMO Clinical Practice Guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer","volume":"32","author":"Gennari","year":"2021","journal-title":"Ann Oncol"},{"issue":"suppl 5","key":"10.1016\/j.esmorw.2026.100722_bib19","doi-asserted-by":"crossref","first-page":"v8","DOI":"10.1093\/annonc\/mdv298","article-title":"Primary breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"26","author":"Senkus","year":"2015","journal-title":"Ann Oncol"},{"issue":"28","key":"10.1016\/j.esmorw.2026.100722_bib20","doi-asserted-by":"crossref","first-page":"3661","DOI":"10.1002\/sim.6607","article-title":"Moving towards best practices when using inverse probability of treatment weighting (IPTW) using the propensity score to estimate causal treatment effects in observational studies","volume":"34","author":"Austin","year":"2015","journal-title":"Stat Med"},{"key":"10.1016\/j.esmorw.2026.100722_bib21","series-title":"Data from the Netherlands Cancer Registry (NCR)","year":"2025"},{"issue":"12","key":"10.1016\/j.esmorw.2026.100722_bib22","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1016\/j.annonc.2023.10.001","article-title":"ESMO guidance for reporting oncology real-world evidence (GROW)","volume":"34","author":"Castelo-Branco","year":"2023","journal-title":"Ann Oncol"},{"issue":"10","key":"10.1016\/j.esmorw.2026.100722_bib23","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2025.105810","article-title":"Access to novel cancer medicines in Europe: inequities across countries and their drivers","volume":"10","author":"Hofmarcher","year":"2025","journal-title":"ESMO Open"},{"issue":"6","key":"10.1016\/j.esmorw.2026.100722_bib24","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2021.100331","article-title":"Variation in chemotherapy prescribing rates and mortality in early breast cancer over two decades: a national data linkage study","volume":"6","author":"Gray","year":"2021","journal-title":"ESMO Open"},{"key":"10.1016\/j.esmorw.2026.100722_bib25","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1186\/1471-2407-14-596","article-title":"Regional variation in breast cancer treatment in the Netherlands and the role of external peer review: a cohort study comprising 63,516 women","volume":"14","author":"Kilsdonk","year":"2014","journal-title":"BMC Cancer"},{"issue":"5","key":"10.1016\/j.esmorw.2026.100722_bib28","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1093\/aje\/kwf068","article-title":"Geocoding and monitoring of US socioeconomic inequalities in mortality and cancer incidence: does the choice of area-based measure and geographic level matter?: the Public Health Disparities Geocoding Project","volume":"156","author":"Krieger","year":"2002","journal-title":"Am J Epidemiol"},{"issue":"8","key":"10.1016\/j.esmorw.2026.100722_bib29","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1016\/j.annonc.2025.04.006","article-title":"ESMO-Magnitude of Clinical Benefit Scale version 2.0 (ESMO-MCBS v2.0)","volume":"36","author":"Cherny","year":"2025","journal-title":"Ann Oncol"}],"container-title":["ESMO Real World Data and Digital Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S294982012600041X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S294982012600041X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T15:39:55Z","timestamp":1790264395000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S294982012600041X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":28,"alternative-id":["S294982012600041X"],"URL":"https:\/\/doi.org\/10.1016\/j.esmorw.2026.100722","relation":{},"ISSN":["2949-8201"],"issn-type":[{"value":"2949-8201","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Treatment and survival of de novo HER2-positive metastatic breast cancer across regional cancer networks in the Netherlands: a cohort study","name":"articletitle","label":"Article Title"},{"value":"ESMO Real World Data and Digital Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.esmorw.2026.100722","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Ltd on behalf of European Society for Medical Oncology.","name":"copyright","label":"Copyright"}],"article-number":"100722"}}